ImmunityBio, Inc.

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
6.32 ^USD	-3.36%		-12.95%	+25.90%

06-20	Sector Update: Health Care Stocks Mixed Thursday Afternoon	MT
06-20	ImmunityBio Shares Rise After Launch of Bladder Cancer Treatment Anktiva in US	MT

Certain shares of NantKwest, Inc.'s Warrants are subject to a Lock-Up Agreement Ending on 24-JAN-2016.

January 23, 2016

Certain shares of NantKwest, Inc.'s Warrants are subject to a Lock-Up Agreement Ending on 24-JAN-2016. These shares will be under lockup for 180 days starting from 28-JUL-2015 to 24-JAN-2016.

Latest news about ImmunityBio, Inc.

Sector Update: Health Care Stocks Mixed Thursday Afternoon	06-20	MT
ImmunityBio Shares Rise After Launch of Bladder Cancer Treatment Anktiva in US	06-20	MT
ImmunityBio's Bladder Cancer Treatment Anktiva Launches in US	06-20	MT
ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA	06-20	CI
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	05-07	MT
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	05-07	CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	05-06	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	05-03	MT
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	05-02	CI
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	04-30	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	04-29	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	04-29	MT
Transcript : ImmunityBio, Inc. - Special Call	04-26
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	04-25	CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer	04-23	MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	04-23	MT
Top Premarket Gainers	04-23	MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva	04-23	DJ
US FDA approves ImmunityBio's bladder cancer therapy	04-23	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	04-23	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	04-22	RE
ImmunityBio Files Mixed Shelf	04-17	MT
North American Morning Briefing : Markets Steady -2-	03-26	DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	03-25	MT

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ImmunityBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.32 USD

Average target price

7.5 USD

Spread / Average Target

+18.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNITYBIO, INC.	+25.90%	4.37B
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs

ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Certain shares of NantKwest, Inc.'s Warrants are subject to a Lock-Up Agreement Ending on 24-JAN-2016.

Latest news about ImmunityBio, Inc.

Chart ImmunityBio, Inc.

Company Profile

Income Statement Evolution

Ratings for ImmunityBio, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs